Literature DB >> 28819071

Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Meijuan Xu1, Deepak Kumar Bhatt1, Catherine K Yeung1, Katrina G Claw1, Amarjit S Chaudhry1, Andrea Gaedigk1, Robin E Pearce1, Ulrich Broeckel1, Roger Gaedigk1, Deborah A Nickerson1, Erin Schuetz1, Allan E Rettie1, J Steven Leeder1, Kenneth E Thummel1, Bhagwat Prasad2.   

Abstract

Hepatic flavin-containing mono-oxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine). To predict the effect of genetic and nongenetic factors on the hepatic metabolism of FMO3 substrates, we quantified FMO3 protein abundance in human liver microsomes (HLMs; n = 445) by liquid chromatography-tandem mass chromatography proteomics. Genotyping/gene resequencing, mRNA expression, and functional activity (with benzydamine as probe substrate) of FMO3 were also evaluated. FMO3 abundance increased 2.2-fold (13.0 ± 11.4 pmol/mg protein vs. 28.0 ± 11.8 pmol/mg protein) from neonates to adults. After 6 years of age, no significant difference in FMO3 abundance was found between children and adults. Female donors exhibited modestly higher mRNA fragments per kilobase per million reads values (139.9 ± 76.9 vs. 105.1 ± 73.1; P < 0.001) and protein FMO3 abundance (26.7 ± 12.0 pmol/mg protein vs. 24.1 ± 12.1 pmol/mg protein; P < 0.05) compared with males. Six single nucleotide polymorphisms (SNPs), including rs2064074, rs28363536, rs2266782 (E158K), rs909530 (N285N), rs2266780 (E308G), and rs909531, were associated with significantly decreased protein abundance. FMO3 abundance in individuals homozygous and heterozygous for haplotype 3 (H3), representing variant alleles for all these SNPs (except rs2066534), were 50.8% (P < 0.001) and 79.5% (P < 0.01), respectively, of those with the reference homozygous haplotype (H1, representing wild-type). In summary, FMO3 protein abundance is significantly associated with age, gender, and genotype. These data are important in predicting FMO3-mediated heteroatom-oxidation of xenobiotics and endogenous biomolecules in the human liver.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28819071      PMCID: PMC5697103          DOI: 10.1124/jpet.117.243113

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  49 in total

Review 1.  Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity.

Authors:  Richard Weinshilboum; Liewei Wang
Journal:  Clin Pharmacol Ther       Date:  2004-04       Impact factor: 6.875

2.  Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue.

Authors:  Johan Botling; Karolina Edlund; Ulrika Segersten; Simin Tahmasebpoor; Mats Engström; Magnus Sundström; Per-Uno Malmström; Patrick Micke
Journal:  Diagn Mol Pathol       Date:  2009-03

3.  Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.

Authors:  Priyanka Parte; David Kupfer
Journal:  Drug Metab Dispos       Date:  2005-06-29       Impact factor: 3.922

4.  N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication.

Authors:  J R Cashman; Y N Xiong; L Xu; A Janowsky
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

5.  Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5.

Authors:  N J Cherrington; Y Cao; J W Cherrington; R L Rose; E Hodgson
Journal:  Xenobiotica       Date:  1998-07       Impact factor: 1.908

6.  Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans.

Authors:  Tomomi Taniguchi-Takizawa; Makiko Shimizu; Toshiyuki Kume; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2014-10-05       Impact factor: 3.614

Review 7.  Role of flavin-containing monooxygenase in drug development.

Authors:  John R Cashman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

8.  PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation.

Authors:  Adam S Gordon; Robert S Fulton; Xiang Qin; Elaine R Mardis; Deborah A Nickerson; Steve Scherer
Journal:  Pharmacogenet Genomics       Date:  2016-04       Impact factor: 2.089

9.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

10.  Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies.

Authors:  Virginie Lattard; Jun Zhang; Quyen Tran; Bjarte Furnes; Daniel Schlenk; John R Cashman
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

View more
  17 in total

Review 1.  Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.

Authors:  Deepak Ahire; Laken Kruger; Sheena Sharma; Vijaya Saradhi Mettu; Abdul Basit; Bhagwat Prasad
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

3.  Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro.

Authors:  M M Parvez; Nazia Kaisar; Ho Jung Shin; Yoon Jae Lee; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver.

Authors:  Deepak Kumar Bhatt; Aanchal Mehrotra; Andrea Gaedigk; Revathi Chapa; Abdul Basit; Haeyoung Zhang; Prachi Choudhari; Mikael Boberg; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

Review 5.  Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.

Authors:  Yadira X Perez-Paramo; Philip Lazarus
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-12-29       Impact factor: 4.481

Review 6.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

Review 7.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

8.  Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.

Authors:  Yadira X Perez-Paramo; Gang Chen; Joseph H Ashmore; Christy J W Watson; Shamema Nasrin; Jennifer Adams-Haduch; Renwei Wang; Yu-Tang Gao; Woon-Puay Koh; Jian-Min Yuan; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-31       Impact factor: 4.254

9.  Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation.

Authors:  Md Masud Parvez; Abdul Basit; Parth B Jariwala; Zsuzsanna Gáborik; Emese Kis; Scott Heyward; Matthew R Redinbo; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2021-06-01       Impact factor: 3.579

Review 10.  Ontogeny of Drug-Metabolizing Enzymes.

Authors:  Aarzoo Thakur; Md Masud Parvez; J Steven Leeder; Bhagwat Prasad
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.